Skip to main content

7 Result(s)

within Yuka Mimura-Kimura Remove this filter

and

  1. Article

    Open Access

    Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma

    The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed solubl...

    Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura… in Scientific Reports (2024)

    Download PDF (1834 KB) View Article

  2. Article

    Open Access

    Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan

    The magnitude and durability of cell-mediated immunity in older and severely frail individuals following coronavirus disease 2019 (COVID-19) vaccination remain unclear. A controlled immune response could be th...

    Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura-Kimura, Keiko Doi… in Immunity & Ageing (2024)

    Download PDF (2942 KB) View Article

  3. No Access

    Article

    Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy

    Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity; however, the clinical impact of these p...

    Riki Okita, Yuka Mimura-Kimura, Nobutaka Kawamoto… in Cancer Immunology, Immunotherapy (2023)

  4. No Access

    Chapter

    Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation

    The complex diantennary-type oligosaccharides at Asn297 residues of the IgG heavy chains have a profound impact on the safety and efficacy of therapeutic IgG monoclonal antibodies (mAbs). Fc glycosylation of a...

    Yusuke Mimura, Radka Saldova, Yuka Mimura-Kimura, Pauline M. Rudd… in Antibody Glycosylation (2021)

  5. No Access

    Chapter

    Micro-Heterogeneity of Antibody Molecules

    Therapeutic monoclonal antibodies (mAbs) are mostly of the IgG class and constitute highly efficacious biopharmaceuticals for a wide range of clinical indications. Full-length IgG mAbs are large proteins that ...

    Yusuke Mimura, Radka Saldova, Yuka Mimura-Kimura, Pauline M. Rudd… in Antibody Glycosylation (2021)

  6. Article

    Open Access

    Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

    Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is ess...

    Yusuke Mimura, Toshihiko Katoh, Radka Saldova, Roisin O’Flaherty… in Protein & Cell (2018)

    Download PDF (2824 KB) View Article

  7. No Access

    Chapter and Conference Paper

    Immunogenicity of Calreticulin-Bound Murine Leukemia Virus Glycoprotein gp90

    Yusuke Mimura, Denise Golgher, Yuka Mimura-Kimura… in Glycobiology and Medicine (2005)